🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in Spain / NCT04927819
Recruiting Observational

Extra-short vs. Non-extra-short Dental Implants Splinted on the Same Prosthesis

NCT04927819 · tracked via the Priya Life Science Spain tracker
Sponsor
Fundación Eduardo Anitua
Phase
Observational
Started
2021-05-11
Last updated
2025-04-17

Condition(s) studied

Partial-edentulism

Investigational drug(s) / intervention(s)

BTI Implant

BTI Implant: BTI Dental implants are non-active medical device, single use, non resterilizable, biocompatible and sterile devices made of alloplastic materials (Titanium) intended to be surgically implanted into alveolar and/or basal bone of the mandible or maxilla to provide support and a means of retention for a dental prosthesis (e.g. bridge, single-tooth, overdenture).

Study summary

The main aim of this prospective study is to analyze the survival rate of short-length implants (\<6.5 mm) in subjects with partial edentulism. Non-short length implant will be used as control arm. Additionally, others clinical parameters (marginal bone loss and prosthetic associated complications) will be measured.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age ≥ 18 years * Have planned a fixed multiple prosthesis supported by implants \<6.5 mm in length and implants ≥ 6.5 mm in length within 15 days before the inclusion of the patient in the study. * Planning of supported prostheses from 2 to 4 implants dental * Have a previously performed CBCT (Cone Beam Computed Tomography) * Availability to be observed during the period of tracing * Signature of the informed consent Exclusion Criteria: * Smokers\> 10 cigarettes / day * Complete prostheses * Unitary prostheses

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Clinica Eduardo Anitua Vitoria-Gasteiz Spain Recruiting

More Fundación Eduardo Anitua trials in Spain

Narrow Dental Implants in Multiple Fixed Prosthesis: A Controlled Clinical Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04927819 on ClinicalTrials.gov ↗ ← All trials in Spain